Opendata, web and dolomites

P-TEV TERMINATED

Personalized Tissue-Engineered Veins as the first Cure for Patients with Chronic Venous Insufficiency

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 P-TEV project word cloud

Explore the words cloud of the P-TEV project. It provides you a very rough idea of what is the project "P-TEV" about.

autologous    medicine    patients    constitutes    turns    structural    matrix    medical    acute    grant    small    scaffold    healthcare    medicines    stage    subsequently    steppingstone    donor    break    properly    found    suitable    tissue    allogeneic    gap    cells    deep    grafts    approval    intact    venous    paradigm    first    allotransplantation    decellularized    peripheral    replace    vein    fill    bicuspid    synthetic    regenerative    market    agency    treatment    avoids    2019    rejection    gmp    veins    extracellular    de    functioning    engineered    tev    personalized    immunosuppression    donated    blood    benefit    replacement    foreign    unparalleled    3d    cured    severe    serve    removing    marketing    progressive    added    transplant    budgetary    personalization    chronic    proof    verigraft    function    seeded    positioned    valves    dysfunctional    risks    leg    cvi    patient    clinical    recellularization    ulceration    relief    commercialize    vessels    vascular    clean    immunogenic    too    breakthrough    surgery    insufficiency    dna   

Project "P-TEV" data sheet

The following table provides information about the project.

Coordinator
VERIGRAFT AB 

Organization address
address: ARVID WALLGRENS BACKE 20
city: GOTEBORG
postcode: 413 46
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website http://www.verigraft.com
 Total cost 2˙184˙603 €
 EC max contribution 2˙184˙603 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-09-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    VERIGRAFT AB SE (GOTEBORG) coordinator 2˙184˙603.00

Map

 Project objective

This project will commercialize P-TEV - a unique personalized tissue engineered vein for the treatment of patients with severe Chronic Venous Insufficiency (CVI). CVI is a progressive medical condition in which the valves of the deep veins of the leg are not functioning properly. The most severe stage is CVI with leg ulceration. No effective treatment is available, and a large number of patients would directly benefit from venous vascular surgery. These patients cannot be cured today because no suitable grafts for replacement of the dysfunctional venous valves have yet been developed. There are no synthetic products which could replace the function of the bicuspid valves found in the leg veins and the risks associated with allotransplantation are too high. VERIGRAFT’s technology is the first one positioned to break this paradigm and fill the existing market gap. The technology allows the personalization of blood vessels by de- and recellularization. In short, a donated tissue is decellularized, removing all immunogenic donor cells and DNA. This results in a clean extracellular matrix scaffold with intact 3D structural properties. Subsequently, this scaffold is seeded with the patient´s own cells, derived from a small sample of peripheral blood. This unique technology turns an allogeneic (“foreign”) tissue into an autologous (“personalized”) one and thus avoids transplant rejection without the need for immunosuppression. The clinical proof-of-concept for P-TEV is established. The project will include the clinical study and GMP process development that will grant VERIGRAFT market access by 2019 and serve as a steppingstone to marketing approval by the European Medicines Agency. The EU-added value of the project is unparalleled, as it constitutes a breakthrough in one of future medicine's most promising fields – advanced personalized regenerative medicine, bringing significant long-term budgetary relief to healthcare systems.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "P-TEV" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "P-TEV" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PREFERABLE (2019)

Project on Exercise for Fatigue Eradication in Advanced Breast cancer to improve quality of life

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More  

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More